CBS 2019
CBSMD教育中心
中 文

Scientific Library

Abstract

Recommended Article

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Symptom-Onset-To-Balloon Time, ST-Segment Resolution and In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in China: From China Acute Myocardial Infarction Registry Fine particulate air pollution and hospital admissions and readmissions for acute myocardial infarction in 26 Chinese cities Management of Myocardial Revascularization Failure: An Expert Consensus Document of the EAPCI Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction Optimal Timing of Intervention in NSTE-ACS Without Pre-Treatment The EARLY Randomized Trial

Clinical Trial2020 Nov 7;41(42):4114-4123.

JOURNAL:Eur Heart J. Article Link

Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial

J Tuñón, PG Steg, ODYSSEY OUTCOMES Investigators et al. Keywords: chronic kidney disease; glomerular filtration rate; Low-density lipoprotein cholesterol; MACE; PCSK9 inhibition

Full Text PDF